Key points from article :
Precision Neuroscience's groundbreaking research revolves around their brain-computer interface (BCI) technology, which has earned FDA breakthrough device designation.
The BCI utilises 1,024 tiny electrodes on a flexible film, specifically designed for implantation by neurosurgeons.
This film, incredibly thin at one-fifth the width of a human hair, can be removed without causing damage to the brain tissue.
The primary focus of their research is to map extensive areas of the brain's surface with significantly higher resolutions than traditional neurosurgical techniques.
Founded in 2021, Precision Neuroscience initiated a pilot clinical study in June of the current year, marking a significant milestone in their research journey.
Although the Precision Neuroscience BCI is still investigational and not available for purchase in the U.S., the company aims to secure regulatory approval by 2024, signifying their commitment to advancing the field of neurotechnology.